<DOC>
	<DOCNO>NCT02530476</DOCNO>
	<brief_summary>There 2 part study : Part 1 ( dose escalation ) Part 2 ( dose expansion ) . The goal Part 1 clinical research study find high tolerate dose combination selinexor ( KPT-330 ) sorafenib ( Nexavar ) give patient FLT3-ITD -D835 mutate AML FLT3-mutated high-risk MDS . The goal Part 2 study learn dose find Part 1 help control disease . The safety drug combination also study part study .</brief_summary>
	<brief_title>Phase I/II , Study Selective Inhibitor Nuclear Export ( SINE ) Selinexor ( KPT-330 ) + Sorafenib Acute Myeloid Leukemia</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , assign study group base join study . Up 3 group 6 participant enrol Part 1 study , 40 participant enrol Part 2 . If enrol Part 1 , dose selinexor sorafenib receive depend join study . The first group participant receive start dose combination level . If intolerable side effect see , next group receive high dose selinexor sorafenib Group 1 . If intolerable side effect see , next group may receive low dose level selinexor and/or sorafenib . This continue high tolerable combination dose find . If enrol Part 2 , receive selinexor sorafenib high tolerable combination dose effective combination dose find Part 1 . Study Drug Administration : Each study cycle 28 day . However , study cycle may 3-12 week long , depend if/how disease respond treatment , bone marrow react treatment , doctor think best interest . You take selinexor tablet mouth 2 time week ( Monday/Wednesday Tuesday/Thursday Wednesday/Friday ) 3 week . You must take dose selinexor within 30 minute eat , least 4 ounce fluid ( either water , milk , juice , ) . You must swallow tablet whole . Do crush . If powder come contact skin , may increase chance skin-related side effect . You take sorafenib mouth 2 time day , every day . Depending disease responds study drug , number day receive study drug may change . Your doctor discus . You must take dose sorafenib least 1 hour 1 hour eating . You give drug diary ask write time take study drug every day . You must bring study drug diary unused study drug bottle study visit . Study Visits : On Day 1 Cycles 1-4 every 1-3 cycle : - You physical exam . - You EKG . The study doctor tell often test Cycle 4 . One time week Cycles 1-3 , blood ( 1 tablespoon ) drawn routine test . After Cycle 3 , blood draw 1 time every 2-4 week . If doctor think need , blood may need drawn often 1 tablespoon blood may need drawn . After Cycle 1 , may able blood draw perform local lab clinic closer home . The result test send MD Anderson review . The study doctor study staff discus option . On Day 28 Cycles 1 3 ( +/- 7 day ) every 1-3 cycle , bone marrow aspiration and/or biopsy check status disease . Every 3 month ( +/- 14 day ) , become pregnant , blood ( 1-2 tablespoon ) urine collect pregnancy test . If stay study 6 month side effect , may test less often . The study doctor discus . Length Study : You may continue take study drug long study doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study follow-up visit . End-of-Study Visit : If stop take study drug end Cycle 24 : - You physical exam . - Blood ( 2-3 tablespoon ) draw routine test . - If doctor think need , bone marrow aspirate check status disease . Follow-Up : About 30 day ( +/- 7 ) last dose study drug , physical exam . You may exam MD Anderson local clinic near home . If exam local clinic , result exam sent MD Anderson review . If come MD Anderson local clinic , call member study staff ask side effect and/or start new treatment ( ) . This call last 5 minute . Long-Term Follow-Up : If disease appear get well respond well study drug , return MD Anderson every 3-6 month 5 year last dose study drug study staff check . If return MD Anderson visit , may call member study staff . The call last 10 minute . This investigational study . Sorafenib FDA approve commercially available treat hepatocellular cancer . Selinexor FDA approve commercially available . It currently use research purpose . The combination selinexor sorafenib treat FLT3-mutated AML high-risk MDS investigational . The study doctor explain study drug design work . Up 52 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . FLT3ITD and/or FLT3D835 mutate patient 18 year age old relapsed/ refractory AML ( number relapse ) include patient may previously expose one FLT3inhibitor therapy eligible phase I portion study . 2 . Phase II FLT3ITD and/or FLT3D835 mutate relapsed/refractory patient : Patients diagnosis AML ( de novo transform hematologic malignancy ) . Patients highrisk myelodysplastic syndrome ( MDS ) ( define &gt; /= 10 % blast bone marrow ) patient Chronic Myelomonocytic Leukemia ( CMML ) ( &gt; /= 10 % blast bone marrow ) may also eligible discussion Principal Investigator ( PI ) . The patient one follow feature : 1 . Patients AML fail prior induction therapy relapse prior therapy . 2 . Patients highrisk MDS highrisk CMML fail prior therapy MDS CMML . 3 . Patients MDS CMML receive therapy MDS CMML progress AML eligible time diagnosis AML regardless prior therapy AML . The WHO classification use AML . 3 . Patients must eligible one two cohort : Cohort 1 ( FLT3 and/or FLT3D835 inhibitor failure cohort ) FLT3ITD and/or FLT3D835 mutate relapsed/refractory AML fail therapy two prior salvage regimen ( SCT stem cell therapy patient previously underwent SCT/stem cell therapy remission consider salvage regimen ) previously expose least one prior FLT3 inhibitor . Cohort 2 ( FLT3 inhibitor naive cohort ) FLT3ITD and/or FLT3D835 mutate relapsed/refractory fail therapy two prior salvage regimen ( SCT stem cell therapy patient previously underwent SCT/stem cell therapy remission consider salvage regimen ) prior exposure FLT3 inhibitor . 4 . Age &gt; /=18 year 5 . ECOG Performance Status &lt; /=2 6 . Patients estimated life expectancy &gt; 3 month study entry 7 . Adequate hepatic ( serum total bilirubin &lt; /= 2.0 x upper limit normal ( ULN ) ( &lt; /= 3.0 x ULN deem elevated due leukemia ) , alanine aminotransferase and/or aspartate transaminase &lt; /= 3.0 x ULN ( &lt; /= 5.0 x ULN deem elevated due leukemia ) , renal function ( creatinine &lt; /= 2.0 mg/dL ) . 8 . Patients must provide write informed consent . 9 . In absence rapidly progress disease , interval prior treatment time initiation selinexor sorafenib administration least 2 week cytotoxic agent least 5 halflives cytotoxic/noncytotoxic agent . The use chemotherapeutic antileukemic agent permit study follow exception : ( 1 ) intrathecal ( IT ) therapy patient control CNS leukemia discretion PI agreement Sponsor . Controlled CNS leukemia define absence active clinical sign CNS disease evidence CNS leukemia recent 2 simultaneous CSF evaluation . ( 2 ) Use one dose cytarabine ( 2 g/m2 ) hydroxyurea patient rapidly proliferative disease allow start study therapy first four week therapy . These medication record casereport form . 10 . Baseline ejection fraction must &gt; /= 40 % . 11 . Females must surgically biologically sterile postmenopausal ( amenorrheic least 12 month ) childbearing potential , must negative serum urine pregnancy test within 72 hour start treatment . 12 . Women childbearing potential must agree use adequate method contraception study 3 month last treatment . Males must surgically biologically sterile agree use adequate method contraception study 3 month last treatment . Adequate method contraception include : Total abstinence line prefer usual lifestyle patient . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment 13 . ( Continued Criteria 12 ) Male sterilization ( least 6 month prior screen ) . For female patient study , vasectomize male partner sole partner patient Combination two follow ( a+b a+c b+c ) Use oral , injected implant hormonal method contraception form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , example hormone vaginal ring transdermal hormone contraception Placement intrauterine device ( IUD ) intrauterine system ( IUS ) Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/ vaginal suppository 14 . ( Continued Criteria 13 ) In case use oral contraception , woman stable pill take study treatment . Note : Oral contraceptive allow used conjunction barrier method contraception due unknown effect drugdrug interaction . Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week ago . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . 1 . Patients know allergy hypersensitivity selinexor , sorafenib component . 2 . Subject concurrent , uncontrolled medical condition , laboratory abnormality , psychiatric illness , could place him/her unacceptable risk . 3 . Patients major surgical procedure within 14 day Day 1 . 4 . Patients currently receive standard investigational therapy treatment AML . 5 . Patients unwilling unable comply protocol . 6 . Patients receive concomitant treatment strong CYP3A4 inhibitor , unless drug consider critical well patient adequate alternative available . Strong CYP3A4 inhibitor include follow medication : itraconazole , ketoconazole , miconazole , voriconazole ; amprenavir , atazanavir , fosamprenavir , indinavir , nelfinavir , ritonavir ; ciprofloxacin , clarithromycin , diclofenac , doxycycline , enoxacin , isoniazid , ketamine , nefazodone , nicardipine , propofol , quinidine , telithromycin . 7 . Patients severe gastrointestinal metabolic condition could interfere absorption oral medication . 8 . Patients blast transformation chronic myeloid leukemia ( CML ) . Prior MDS CMML acceptable . 9 . Patient concurrent active malignancy treatment . 10 . Unstable cardiovascular function : • Symptomatic ischemia , • Uncontrolled clinically significant conduction abnormality ( i.e. , ventricular tachycardia antiarrhythmic agent exclude ; 1st degree atrioventricular ( AV ) block asymptomatic leave anterior fascicular block/right bundle branch block ( LAFB/RBBB ) exclude ) , • Congestive heart failure ( CHF ) NYHA Class ≥ 3 , • Myocardial infarction ( MI ) within 3 month . • Left ventricular ejection fraction &lt; 40 % . • Hypertension &gt; 140 mm Hg systolic &gt; 90 mm Hg diastolic without antihypertensive therapy . 11 . Uncontrolled infection time enrollment . Infections control concurrent antimicrobial agent acceptable , antimicrobial prophylaxis per institutional guideline acceptable . 12 . Known active hepatitis B virus ( HBV ) C virus ( HCV ) infection ; know positive HCV ribonucleic acid ( RNA ) HBsAg ( HBV surface antigen ) . 13 . Known human immunodeficiency virus ( HIV ) infection . 14 . Female subject pregnant breastfeeding . 15 . Acute promyelocytic leukemia . 16 . Any medical condition , investigator 's opinion , could compromise patient 's safety .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Relapsed/Refractory</keyword>
	<keyword>FLT3-ITD mutation</keyword>
	<keyword>FLT3-mutated high-risk myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Chronic Myelomonocytic Leukemia</keyword>
	<keyword>CMML</keyword>
	<keyword>Selinexor</keyword>
	<keyword>KPT-330</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Nexavar</keyword>
	<keyword>BAY 43-9006</keyword>
	<keyword>FLT3-inhibitor therapy</keyword>
</DOC>